With your own knowledge and the help of the following document:

Document 1 (Title: Pharmacotherapy of Entamoeba histolytica Infections): Amebiasis management requires targeted pharmacological approaches addressing both intestinal and tissue infections through agents with distinctive spectrum and distribution characteristics. Therapeutic approaches typically distinguish between luminal agents effective against intestinal colonization versus tissue amebicides capable of treating invasive disease including hepatic abscesses. Nitroimidazole derivatives represent the cornerstone of tissue amebicide therapy due to their excellent distribution characteristics and direct amebicidal activity in hepatic and other extraintestinal sites. Metronidazole (FLAGYL®) demonstrates excellent tissue penetration and efficacy against invasive amebiasis, achieving therapeutic concentrations in hepatic abscess fluid and other invasive sites. Clinical studies document cure rates exceeding 90% for uncomplicated amebic liver abscess following appropriate metronidazole regimens. Similarly, secnidazole (FLAGENTYL®) provides effective treatment for tissue amebiasis with the advantage of single-dose administration due to its extended half-life compared to other nitroimidazoles. This pharmacokinetic advantage facilitates improved adherence in resource-limited settings while maintaining comparable clinical efficacy. Ornidazole (TIBÉRAL®) represents another effective tissue amebicide within the nitroimidazole class, demonstrating excellent penetration into hepatic tissue and abscess cavities with similar efficacy profiles to other class members. These agents contrast with medications primarily effective against intestinal luminal infection, including paramomycin and diloxanide furoate, which demonstrate poor systemic absorption limiting their utility against tissue invasion. Similarly, antifungal agents including econazole (PEVARYL®) lack amebicidal activity despite activity against certain other parasites, while antihelminthic agents such as flubendazole (FLUVERMAL®) demonstrate no meaningful activity against protozoan pathogens including Entamoeba histolytica. These pharmacological distinctions inform appropriate agent selection for amebiasis, typically requiring nitroimidazole derivatives for tissue invasion followed by luminal agents to prevent recurrence.
Document 2 (Title: Quantitative Analysis of Enzyme-Substrate Interactions): Enzyme kinetics represents the quantitative study of enzyme-catalyzed reactions, providing essential insights into catalytic mechanisms, metabolic regulation, and pharmacological interventions. The Michaelis-Menten model serves as the foundational framework for understanding enzyme behavior under varying substrate concentrations. This model proposes that enzymes (E) reversibly bind substrates (S) to form enzyme-substrate complexes (ES), which subsequently convert to products (P) and regenerated enzyme. Under steady-state conditions, where ES concentration remains constant, reaction velocity varies hyperbolically with substrate concentration according to the equation: v = (Vmax × [S])/(Km + [S]). Two fundamental parameters characterize this relationship: Vmax represents the maximum reaction velocity achieved at saturating substrate concentrations, while Km, the Michaelis constant, equals the substrate concentration at which reaction velocity reaches half-maximal (½Vmax). The Km value provides insight into enzyme-substrate affinity, with lower values generally indicating higher affinity. However, interpretation requires caution as Km incorporates multiple rate constants and may not directly equate to dissociation constants in complex reaction mechanisms. The ratio of these parameters (Vmax/Km) defines the catalytic efficiency, a critical metric for comparing enzymes or assessing evolutionary optimization. Experimental determination of these parameters typically employs initial velocity measurements across a range of substrate concentrations under standardized conditions of temperature, pH, and ionic strength. Linearization methods, such as Lineweaver-Burk (double-reciprocal) plots, facilitates parameter estimation, with 1/v plotted against 1/[S] yielding a straight line with slope Km/Vmax, y-intercept 1/Vmax, and x-intercept -1/Km. While historically valuable, modern computational methods using non-linear regression provide more accurate parameter estimates by avoiding statistical distortion inherent in linearization. The kinetic behavior of hexokinase, a representative enzyme catalyzing glucose phosphorylation, epitomizes these principles with relatively low Km values for glucose, reflecting its physiological role in initiating glycolysis at normal blood glucose concentrations.
Document 3 (Title: Microbiological Characteristics of Beta-Hemolytic Streptococci): Streptococcus pyogenes (Group A Streptococcus) represents a clinically significant gram-positive coccus with distinctive microbiological properties and pathophysiological mechanisms. Laboratory identification utilizes several characteristic features, with hemolytic pattern on blood agar constituting a fundamental distinction. Beta-hemolysis, characterized by complete lysis of erythrocytes creating a clear zone surrounding bacterial colonies, represents the hallmark pattern for Group A Streptococcus. This hemolytic activity derives primarily from two complementary cytolysins: streptolysin O and streptolysin S. Streptolysin O, an oxygen-labile, cholesterol-binding cytolysin, forms transmembrane pores through oligomerization, disrupting cellular integrity. This protein demonstrates antigenic properties, eliciting antibody responses (anti-streptolysin O or ASO) utilized diagnostically as evidence of recent streptococcal infection. In contrast, streptolysin S represents an oxygen-stable, non-antigenic peptide demonstrating potent membrane-damaging properties. The synergistic action of these toxins produces the characteristic zone of complete hemolysis surrounding colonies on blood agar, distinguishing beta-hemolytic streptococci from alpha-hemolytic species (producing partial hemolysis with greenish discoloration) and gamma-hemolytic variants (non-hemolytic). Beyond hemolytic properties, S. pyogenes demonstrates characteristic small colony morphology (1-2 mm diameter), susceptibility to bacitracin (differentiating it from other beta-hemolytic streptococci), positive PYR (L-pyrrolidonyl arylamidase) test, and definitively, the presence of Lancefield group A carbohydrate antigen in the cell wall. The organism's pathogenicity derives from multiple virulence factors including the antiphagocytic M protein, hyaluronic acid capsule, various adhesins, and numerous exotoxins contributing to invasive disease manifestations. Unlike certain other streptococcal species, S. pyogenes can grow aerobically, though it demonstrates enhanced growth under anaerobic or microaerophilic conditions. This facultative nature contrasts with obligate anaerobes requiring oxygen-depleted environments for viability. The organism's exotoxins contribute to both local tissue damage in pharyngeal and skin infections and systemic manifestations including scarlet fever and streptococcal toxic shock syndrome.

Answer the following list question.
Question: Select the medication(s) used as tissue amebicide(s):
Options:
1. Flubendazole (FLUVERMAL®)
2. Metronidazole (FLAGYL®)
3. Secnidazole (FLAGENTYL®)
4. Econazole (PEVARYL®)
5. Ornidazole (TIBÉRAL)

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ← if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.